Real-world OS estimates observed in Swedish patients with advanced NSCLC receiving a PD-(L)1 inhibitor-based regimen in first line were generally similar to what has been reported in pivotal PD-(L)1 inhibitor clinical trials. Here, CD274 is linked to non-small cell lung carcinoma.